4//SEC Filing
Erbez Georgia 4
Accession 0001209191-22-040229
CIK 0001290149other
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 4:25 PM ET
Size
5.9 KB
Accession
0001209191-22-040229
Insider Transaction Report
Form 4
Erbez Georgia
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2022-07-01−18,000→ 0 totalExercise: $17.76Exp: 2031-06-02→ Common Stock (18,000 underlying)
Footnotes (2)
- [F1]The options vest at the rate of 2.778% monthly, beginning on the one-month anniversary of the grant date, with 100% vested on the three-year anniversary of the grant date, subject to the provision of service by the Reporting Person to the Issuer on each vesting date.
- [F2]Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
Documents
Issuer
Sierra Oncology, Inc.
CIK 0001290149
Entity typeother
Related Parties
1- filerCIK 0001557930
Filing Metadata
- Form type
- 4
- Filed
- Jun 30, 8:00 PM ET
- Accepted
- Jul 1, 4:25 PM ET
- Size
- 5.9 KB